2017 MacLean Lecture Series
The 2017 MacLean Lecture Series will be held Thursday, May 18th and Friday May 19, 2017. Our guest lecturer is Prof. David MacMillan, the James S. McDonnell Distinguished University Professor of Chemistry at Princeton University. Prof. MacMillan’s research focuses on the discovery and understanding of novel catalytic processes, and their application towards complex targets. He is well known for his pioneering contributions in the field of organocatalysis and photoredox catalysis. His work has been recognized with many awards, prizes and honours, including the Ernst Schering Prize, the Harrison Howe Award and the Mukaiyama Award, among many others. He is also a Fellow of the Royal Society and is a member of the American Academy of Arts and Sciences. More information on his research can be found here.
Every year, research groups in chemistry and chemical biology are given the chance to meet with the MacLean lecturer for about 30 minutes. This is an excellent opportunity to have a discussion with a world-class chemist doing high-impact research. If you or your group is interested in meeting with Dr. MacMillan, please fill out the following poll, https://doodle.com/poll/vchn4gnptgrght5a. A finalized list of meeting times will be sent out in early May. If you have any questions, please feel free to contact me.
Best Regards,
Alex Nielsen
2015-2016 MCGSS President
Related News
News Listing
![Image of Vassili Kanellis](https://chemistry.mcmaster.ca/app/uploads/2024/04/vassili-e1713486674605.jpg)
April 17, 2024
![Photo of Professor Gary J. Schrobilgen in front of a period table of elements display](https://chemistry.mcmaster.ca/app/uploads/2024/04/Gary_J_Schrobilgen_Photo_2024.png)
La Fondation de la Maison de la Chimie ➚
Prof. Schrobilgen Awarded 2024 International Henri Moissan Prize
Uncategorized
April 1, 2024
![John Valliant with Fusion Pharmaceuticals banner](https://chemistry.mcmaster.ca/app/uploads/2023/05/Fusion.png)
McMaster Daily News ➚
AstraZeneca moves to acquire Dr. Valliant founded Fusion Pharmaceuticals for $2.4 billion (US)
Uncategorized
March 21, 2024